title: Postprandial intestinal-derived chylomicron and chylomicron remnants in essential hypertensive patients before and after prolonged captopril therapy.
abstract: The metabolism of the postprandial intestinal-derived lipoproteins, chylomicron and chylomicron remnants, is not known in patients with essential hypertension. After a fat meal, using the vitamin A test as a marker, retinyl palmitate was measured in the total plasma, chylomicron, and chylomicron remnant fractions in 14 untreated nondiabetic essential hypertensive patients with normal fasting lipids and lipoproteins. The vitamin A fat loading test was repeated in eight hypertensive patients after 3 months of captopril therapy. Fifteen matched normotensive subjects were used as controls. The untreated essential hypertensive patients had significantly higher chylomicron fraction concentration curves (AUC 17,469 +/- 2553 micrograms/L/h) P < .001 compared with the control group (AUC 13,208 +/- 1245 micrograms/L/h), by two-way analysis of variance with repeated measurements. After 3 months of captopril therapy, the chylomicron fraction (AUC 9701 +/- 1566 micrograms/L/h), and chylomicron remnants fraction (AUC 3487 +/- 580 micrograms/L/h) were much lower (P < .001) than before captopril therapy. Oral glucose tolerance tests were borderline in five of the eight hypertensives before captopril treatment but returned to normal after 3 months of therapy. In summary, postprandial intestinal-derived lipoprotein metabolism is altered in essential hypertensive patients. Captopril therapy caused significant improvement in the postprandial chylomicron metabolism.
authors.affiliation: Department of Nephrology, Tel Aviv Medical Center, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Iaina
authors.forename: D S
authors.initials: DS
authors.lastname: Silverberg
authors.forename: Y
authors.initials: Y
authors.lastname: Wollman
authors.forename: R
authors.initials: R
authors.lastname: Judevics
authors.forename: R
authors.initials: R
authors.lastname: Baruch
authors.forename: C
authors.initials: C
authors.lastname: Levhar
authors.forename: G
authors.initials: G
authors.lastname: Peer
authors.forename: M
authors.initials: M
authors.lastname: Blum
authors.forename: I
authors.initials: I
authors.lastname: Grosskopf
authors.forename: M S
authors.initials: MS
authors.lastname: Weintraub
mesh_terms: D002216:Captopril / Q000627:therapeutic use*; D002914:Chylomicrons / Q000187:drug effects / Q000378:metabolism*; D004041:Dietary Fats / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D002914:Chylomicrons; D004041:Dietary Fats; D002216:Captopril